Skip to content

Study · Observational study · n = 23,106 · 2026

4 results

Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.

Wu JY, Lin YM, Hsu WH, Liu TH, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC

Hepatology international14 Jan 2026

PMID41535629 (opens in a new tab)DOI10.1007/s12072-025-11021-z (opens in a new tab)PepBankPUB-41535629
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with MASLD, tirzepatide was associated with a lower risk of the composite of mortality, major adverse cardiovascular events and major adverse liver outcomes than SGLT2 inhibitors (HR 0.72).

    In plain wordsIn adults with fatty liver disease (MASLD), tirzepatide was linked to fewer deaths, heart events and liver events combined than SGLT2 inhibitors.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of all-cause mortality, MACE and MALO
    Study

    n = 23,106

    Comparator
    SGLT2 inhibitors
    Analysis
    Primary
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.72 HR
    primary composite outcome

    Source sentences

    Summary
    Compared to SGLT2i, TZP use was associated with a significantly lower risk of the primary composite outcome (HR, 0.72; 95% CI, 0.63-0.83).
    2 context sentences
    Summary · context
    Adults (≥ 18 years) with a diagnosis of MASLD who were newly initiated on TZP or SGLT2i between January 1, 2022, and June 30, 2025, were included.
    Summary · context
    After 1:1 propensity score matching, 23,106 patients were included in each group.
  2. 02HumanObservational studyEfficacy outcome

    In adults with MASLD, tirzepatide was associated with a lower risk of all-cause mortality than SGLT2 inhibitors (HR 0.55).

    In plain wordsIn adults with fatty liver disease (MASLD), tirzepatide was linked to a lower risk of death than SGLT2 inhibitors.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 23,106

    Comparator
    SGLT2 inhibitors
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.55 HR
    all-cause mortality

    Source sentences

    Summary
    TZP was also associated with lower risks of all-cause mortality (HR, 0.55; 95% CI, 0.43-0.71)
    2 context sentences
    Summary · context
    Adults (≥ 18 years) with a diagnosis of MASLD who were newly initiated on TZP or SGLT2i between January 1, 2022, and June 30, 2025, were included.
    Summary · context
    After 1:1 propensity score matching, 23,106 patients were included in each group.
  3. 03HumanObservational studyEfficacy outcome

    In adults with MASLD, tirzepatide was associated with a lower risk of major adverse cardiovascular events than SGLT2 inhibitors (HR 0.68).

    In plain wordsIn adults with fatty liver disease (MASLD), tirzepatide was linked to fewer major heart events than SGLT2 inhibitors.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMACE
    Study

    n = 23,106

    Comparator
    SGLT2 inhibitors
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.68 HR
    MACE

    Source sentences

    Summary
    TZP was also associated with lower risks of all-cause mortality (HR, 0.55; 95% CI, 0.43-0.71), MACEs (HR, 0.68; 95% CI, 0.58-0.80)
    2 context sentences
    Summary · context
    Adults (≥ 18 years) with a diagnosis of MASLD who were newly initiated on TZP or SGLT2i between January 1, 2022, and June 30, 2025, were included.
    Summary · context
    After 1:1 propensity score matching, 23,106 patients were included in each group.
  4. 04HumanObservational studyEfficacy outcome

    In adults with MASLD, tirzepatide was associated with a lower risk of major adverse liver outcomes than SGLT2 inhibitors (HR 0.66).

    In plain wordsIn adults with fatty liver disease (MASLD), tirzepatide was linked to fewer major liver events than SGLT2 inhibitors.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse liver outcomes (MALO)
    Study

    n = 23,106

    Comparator
    SGLT2 inhibitors
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.66 HR
    MALO

    Source sentences

    Summary
    TZP was also associated with lower risks of all-cause mortality (HR, 0.55; 95% CI, 0.43-0.71), MACEs (HR, 0.68; 95% CI, 0.58-0.80), and MALOs (HR, 0.66; 95% CI, 0.54-0.80).
    2 context sentences
    Summary · context
    Adults (≥ 18 years) with a diagnosis of MASLD who were newly initiated on TZP or SGLT2i between January 1, 2022, and June 30, 2025, were included.
    Summary · context
    After 1:1 propensity score matching, 23,106 patients were included in each group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.